Core Insights - Atossa Therapeutics has been awarded the Research and Development Award in the Precision Endocrine Therapy category at the 2025 Clinical Trials Arena Excellence Awards for its work on (Z)-endoxifen [1][3] Group 1: Product Development - (Z)-endoxifen is a selective estrogen receptor modulator/degrader (SERM/D) designed to provide consistent systemic exposure independent of CYP2D6 metabolism, with applications in metastatic, neoadjuvant, adjuvant breast cancer, and Duchenne Muscular Dystrophy (DMD) [2][4] - The therapy has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition [4] Group 2: Company Strategy - Atossa emphasizes disciplined capital allocation, focusing on programs that can enable future regulatory submissions and potential commercialization [6] - The company is supported by a growing global intellectual property portfolio, including multiple recently issued U.S. patents and numerous pending applications worldwide [5] Group 3: Leadership and Innovation - The award reflects the company's commitment to precision endocrine therapy and its integrated approach to developing (Z)-endoxifen for patients with high unmet medical needs [3] - The Clinical Trials Arena Excellence Awards recognize companies demonstrating scientific rigor, innovation, and leadership in clinical research and drug development [3]